Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725520 | 0.85 | CRHR1 (0.43) | EPHX2CRHR1PPARGAKR1C3AKR1C2 | |
| SCHEMBL19879081 | 0.81 | EPHX2 (0.40) | EPHX2CRHR1PPARGLIMK1AKR1C3 | |
| SCHEMBL23251392 | 0.79 | CNR1 (0.37) | PPARGPTGESALOX5PPARA | |
| SCHEMBL21725505 | 0.78 | CRHR1 (0.40) | EPHX2CRHR1PPARGLIMK1AKR1C3 | |
| SCHEMBL13784396 | 0.78 | AR (0.43) | EPHX2CRHR1LIMK1AKR1C3AKR1C2 | |
| SCHEMBL16442494 | 0.78 | MMP13 (0.40) | MMP13L3MBTL1 | |
| SCHEMBL23015832 | 0.77 | CRHR1 (0.43) | EPHX2CRHR1PPARGAKR1C3AKR1C2 | |
| SCHEMBL23251395 | 0.75 | CNR1 (0.37) | — | |
| SCHEMBL16442489 | 0.75 | HSD11B1 (0.40) | — | |
| SCHEMBL16442477 | 0.75 | HSD11B1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | EPHX2 3843/4885CRHR1 4681/4885MMP13 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.